Investors Urged to Join Capricor Therapeutics Class Action Lawsuit for Securities Fraud

Investors Encouraged to Join Class Action Lawsuit Against Capricor Therapeutics

The Rosen Law Firm, noted for its commitment to investor rights, is reminding investors involved with Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding a significant securities fraud lawsuit. Those who purchased Capricor securities between October 9, 2024, and July 10, 2025, should note that they have until September 15, 2025, to take actionable steps in this ongoing litigation.

Why This Lawsuit Matters

If you bought shares in Capricor during the specified period, you could be eligible for compensation without any upfront costs through a contingency fee arrangement. This means you can participate in the lawsuit without worrying about out-of-pocket expenses, as attorneys' fees are only paid if the case is won.

Take Action Now

To join the class action, interested investors can visit Rosen Legal's website or get in touch with Phillip Kim, a leading attorney at the firm, via phone at 866-767-3653 or through email at [email protected] It is imperative for those wishing to take on the role of lead plaintiff to act swiftly, as the court’s deadline approaches.

Understanding the Role of Lead Plaintiffs

The lead plaintiff is essentially tasked with representing the interests of all affected investors. Their responsibility includes directing the litigation process, making judicial decisions, and aligning the course of the case with the best interests of the entire class. Given the complexities involved in these types of lawsuits, selecting qualified counsel is critical.

Rosen Law Firm is recognized for its success in navigating such waters, having achieved the largest securities class action settlement involving a Chinese company at the time and consistently ranked among the top firms in this field. Further, they have a proven track record of recovering significant amounts for investors, including over $438 million in 2019 alone.

Details of the Case Against Capricor

The allegations in the Capricor case point towards misleading statements made by the company that were intended to bolster investor confidence. Throughout the specified Class Period, Capricor provided what were deemed materially beneficial updates regarding their lead candidate drug, deramiocel, which targets cardiomyopathy linked to Duchenne muscular dystrophy (DMD).

While Capricor promoted its prospects for obtaining a Biologics License Application (BLA) from the FDA, the company was simultaneously misrepresenting crucial safety and efficacy data from its Phase 2 HOPE-2 trial concerning deramiocel. As a result, many investing decisions were based on artificially inflated prices that did not reflect reality. Once the truth about the drug's viability emerged, investors incurred substantial losses.

Join the Movement

Investors are reminded that no class has been certified at this moment, so any individuals wishing to join should consider retaining their own counsel or deciding to remain as part of the class but without active representation at this point. It is also important to highlight that a claim to a possible future recovery is not dependent on being a lead plaintiff.

For ongoing updates, investors can follow Rosen Law Firm’s activities on LinkedIn, Twitter, and Facebook.

Attorney advertising rules apply, and prior results do not guarantee the same outcome in future cases.

To summarize, this is a significant opportunity for Capricor Therapeutics investors to join a legal movement that can potentially yield compensation for losses incurred due to alleged securities fraud.